FATE THERAPEUTICS INC Repayments of Long-Term Debt
FATE THERAPEUTICS INC (FATE) reported Repayments of Long-Term Debt of $15.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2022-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2022-02-28
- FATE THERAPEUTICS INC repayments of long-term debt for the quarter ending 2019-12-31 was $14.00M.
- FATE THERAPEUTICS INC repayments of long-term debt for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- FATE THERAPEUTICS INC repayments of long-term debt for the quarter ending 2017-09-30 was $6.71M, a 246.18% increase year-over-year.
- FATE THERAPEUTICS INC repayments of long-term debt for the quarter ending 2017-06-30 was $2.04M, a 7.41% increase year-over-year.
- FATE THERAPEUTICS INC repayments of long-term debt for fiscal 2019 was $15.00M.
- FATE THERAPEUTICS INC repayments of long-term debt for fiscal 2017 was $10.76M, a 39.99% increase from fiscal 2016.
- FATE THERAPEUTICS INC repayments of long-term debt for fiscal 2016 was $7.69M, a 397.35% increase from fiscal 2015.
- FATE THERAPEUTICS INC repayments of long-term debt for fiscal 2015 was $1.55M, a 11.66% decline from fiscal 2014.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month | Repayments of Long-term Debt 77 month | Repayments of Long-term Debt 80 month | Repayments of Long-term Debt 83 month |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $15.00M 10-K · filed 2022-02-28 | |||||
| 2019-09-30 | $1.00M 10-Q · filed 2020-11-05 | ||||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $6.71M derived: sum of 2 quarters · filed 2020-03-02 | $8.75M derived: sum of 3 quarters · filed 2020-03-02 | $10.76M 10-K · filed 2020-03-02 | |||
| 2017-09-30 | $6.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $8.75M derived: sum of 2 quarters · filed 2018-11-01 | $10.76M 10-Q · filed 2018-11-01 | $12.74M derived: sum of 4 quarters · filed 2019-03-05 | |||
| 2017-06-30 | $2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $4.05M 10-Q · filed 2018-08-06 | $6.03M derived: sum of 3 quarters · filed 2019-03-05 | $7.97M derived: sum of 4 quarters · filed 2019-03-05 | |||
| 2017-03-31 | $2.01M 10-Q · filed 2018-05-10 | $3.99M derived: sum of 2 quarters · filed 2019-03-05 | $5.92M derived: sum of 3 quarters · filed 2019-03-05 | $7.83M derived: sum of 4 quarters · filed 2019-03-05 | |||
| 2016-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $3.91M derived: sum of 2 quarters · filed 2019-03-05 | $5.82M derived: sum of 3 quarters · filed 2019-03-05 | $7.69M 10-K · filed 2019-03-05 | |||
| 2016-09-30 | $1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $3.84M derived: sum of 2 quarters · filed 2017-11-01 | $5.71M 10-Q · filed 2017-11-01 | $6.65M derived: sum of 4 quarters · filed 2018-03-05 | |||
| 2016-06-30 | $1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $3.78M 10-Q · filed 2017-08-14 | $4.71M derived: sum of 3 quarters · filed 2018-03-05 | ||||
| 2016-03-31 | $1.87M 10-Q · filed 2017-05-15 | $2.81M derived: sum of 2 quarters · filed 2018-03-05 | |||||
| 2015-12-31 | $935.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $1.55M 10-K · filed 2018-03-05 | |||||
| 2015-09-30 | $611.00K 10-Q · filed 2016-11-07 | ||||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $750.00K derived: sum of 2 quarters · filed 2017-03-16 | $1.25M derived: sum of 3 quarters · filed 2017-03-16 | $1.75M 10-K · filed 2017-03-16 | |||
| 2014-09-30 | $750.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | $1.25M derived: sum of 2 quarters · filed 2015-11-03 | $1.75M 10-Q · filed 2015-11-03 | $2.25M derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2014-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $1.00M 10-Q · filed 2015-08-05 | $1.50M derived: sum of 3 quarters · filed 2016-03-03 | $2.00M derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2014-03-31 | $500.00K 10-Q · filed 2015-05-07 | $1.00M derived: sum of 2 quarters · filed 2016-03-03 | $1.50M derived: sum of 3 quarters · filed 2016-03-03 | $2.00M derived: sum of 4 quarters · filed 2016-03-03 | $6.83M 10-Q · filed 2014-05-13 | ||
| 2013-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $1.00M derived: sum of 2 quarters · filed 2016-03-03 | $1.50M derived: sum of 3 quarters · filed 2016-03-03 | $2.00M 10-K · filed 2016-03-03 | $4.65M 10-K · filed 2014-03-17 | ||
| 2013-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $1.00M derived: sum of 2 quarters · filed 2014-11-12 | $1.50M 10-Q · filed 2014-11-12 | $4.15M 10-Q · filed 2013-11-13 | |||
| 2013-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $1.00M 10-Q · filed 2014-08-12 | |||||
| 2013-03-31 | $500.00K 10-Q · filed 2014-05-13 | ||||||
| 2012-12-31 | $250.00K 10-K · filed 2015-03-12 | ||||||
| 2011-12-31 | $800.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |